An interventional study of Ablation in ECG Brugada Pattern, sponsored by IRCCS Policlinico S. Donato. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-10-02.
Sponsored by IRCCS Policlinico S. Donato · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Brugada Syndrome with a site in Italy — 5 open to participants now, 5 under way, none of them phase 3. Brugada Syndrome · Italy.
Among the 12 studies in Brugada Syndrome with a site in Italy, this one is one of 2 that started in 2017, is one of 5 with no phase, and was the 4th registered.
53 studies on the registry are indexed under Brugada Syndrome; 19 are open to participants now.
Browse Brugada Syndrome studies →5 of the 12 studies in Brugada Syndrome with a site in Italy are open now. Recruiting first, the newest first:
IRCCS Policlinico S. Donato · Sites in Italy
Ages 18+
Maria Cecilia Hospital · Sites in Italy
Ages 18+
University of Campania Luigi Vanvitelli · Sites in Italy
Ages 16+
IRCCS Policlinico S. Donato · Sites in Italy
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 15 Brugada Syndrome studies recruiting now, 10 (67%) set no upper age limit and none (0%) stop at 75 or younger; 6 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 2 started in 2017.
This study's planned enrollment of 300 is above the median of 112 across 18 interventional studies indexed under Brugada Syndrome.
Median enrollment 140 across the 6 interventional studies, 165 across the 6 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 12 has an industry lead sponsor. The 8 most frequent:
IRCCS Policlinico S. Donato is the lead sponsor of 105 studies on the registry; 53 are open to participants now.
IRCCS Policlinico S. Donato has 5 studies filed under Brugada Syndrome — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Brugada Syndrome with a site in Italy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study represents an extension of a previous study (NCT02641431) on the acute and long-term benefit of epicardial ablation on elimination of both BrS-ECG pattern and VT/VF inducibility in 500 consecutive BrS patients.
According to previous protocol (NCT02641431), 300 additional consecutive selected patients having an ICD implantation will be enrolled up to a total of 500 BrS patients. Echocardiography with cardiac deformation analysis, three-dimensional color-coded voltage, activation and duration electroanatomical maps before and after ajmaline (1mg/kg in 5 minutes) wiil determine the site and the size of the arrhythmogenic substrate as characterized by abnormally prolonged fragmented ventricular potentials and potential wall motion abnormalities. Primary endpoint will be identification and elimination of this electrophysiological substrate by RF applications leading to ECG pattern normalization and VT/VF non-inducibility before and after ajmaline. Patients will be followed up to 10 years after ablation by sequential 12-lead ECG and Holter recording, Echocardiography, ICD interrogation, VT/VF inducibility patterns before and after ajmaline test.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Radiofrequency epicardial ablation
Procedure: Ablation
Epicardial Radiofrequency ablation
Type 1 BrS-ECG pattern elimination by epicardial ablation before and after ajmaline test.
Normalization of ECG pattern after elimination by radio-frequency ablation of all abnormal epicardial potentials
Time frame: 1 day after ablation
VT/VF inducibility
Programmed stimulation was achieved at twice the diastolic threshold and randomly performed at RV apex and RV outflow tract using up to 3 drive cycle lengths (from 600 to 350ms) and up to three extrastimuli (S2-S4) delivered from the apex and outflow tract of the right ventricle.
Time frame: immediately after mapping and ablation
Absence of VT/VF
Absence of VT/VF by ICD interrogation
Time frame: 1,3,6,12,18,24,36,48,60,72,84,96,108,120 months after ablation
Absence of Br Pattern and RV mechanical abnormalities using echo and cardiac deformation analysis before and after ajmaline test
Abolition of typical BrS-ECG pattern and RV mechanical abnormalities before and after ajmaline.
Time frame: 3 months
Absence of VA episodes at EP study
Non-inducibility of VT/VT at programmed electrophysiological study
Time frame: 3 months
Absence of Br Pattern at ajmaline test
Normalization of 12-lead ECG recording and echo parameters at baseline and after ajmaline test
Time frame: 6 months
Absence of VA episodes
ICD interrogation
Time frame: 6 months
Absence of VA episodes
ICD interrogation and ajmaline test
Time frame: 12 months
Absence of Br Pattern at ajmaline test
Normalization of 12-lead ECG recording and echo parameters at baseline and after ajmaline test
Time frame: 12 months
Absence of Br Pattern at ajmaline test
Normalization of 12-lead ECG recording at baseline and after ajmaline test
Time frame: 18 months
Absence of VA episodes
ICD interrogation
Time frame: 24 months
Absence of Br ECG pattern after ajmaline test
Normalization of 12-lead ECG recording at baseline and after ajmaline test
Time frame: 24 months
Absence of VA episodes at EP study
ICD interrogation
Time frame: 36 months
Absence of Br Pattern at ajmaline test
Normalization of 12-lead ECG recording at baseline and after ajmaline test
Time frame: 36 months
Absence of Br Pattern at ajmaline test
Normalization of 12-lead ECG recording at baseline and after ajmaline test
Time frame: 48 months
Absence of VA episodes at EP study
ICD interrogation
Time frame: 48 months up to 120 months
Plan to share: No
Started Mar 2017 (actual). Primary completion is estimated for Sep 2023, 78 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.